Jonathan P. T. Corcoran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan P. T. Corcoran has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Carl Hobbs
Neuroscience Drug Discovery Unit, Wolfson Sensory, Pain and Regeneration Centre King's College London UK
10 shared publicationsMaria B. Goncalves
Neuroscience Drug Discovery Unit, Wolfson Sensory, Pain and Regeneration Centre King's College London UK
10 shared publicationsJohn Grist
Neuroscience Drug Discovery Unit, Wolfson Sensory, Pain and Regeneration Centre, King's College London, Guy's Campus, London, United Kingdom
7 shared publicationsJulian Jack
Neuroscience Drug Discovery Unit, Wolfson Sensory, Pain and Regeneration Centre, King's College London, Guy's Campus, London, United Kingdom
7 shared publicationsEarl Clarke
Neuroscience Drug Discovery Unit, Wolfson Sensory, Pain and Regeneration Centre King's College London UK
6 shared publications- Earl Clarke
The Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London SE1 1UL, United Kingdom
5 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in FEBS Open Bio
Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder for which effective disease‐modifying therapies remain limited. Accumulation of neuronal DNA double‐strand breaks (DSBs) is an early pathological event that contributes to genomic instability and neuronal vulnerability in AD. Therapeutic strategies that enhance DNA repair may therefore be of considerable interest. Here, using the Tg2576 mouse model of AD, we show that treatment with KCL‐286, a selective retinoic acid receptor‐β (RARβ) agonist, reduces neuronal DNA damage. KCL‐286 enhances DSB repair in neurons, in part through upregulation of the DNA repair factor BRCA1, while also attenuating neuroinflammatory activation. In addition, KCL‐286 normalises microglial and astrocytic morphology, consistent with reduced pathological glial activation. Together, these findings demonstrate that selective RARβ activation ameliorates neuronal DNA damage and neuroinflammation in a mouse model of AD, supporting further investigation as a potential disease‐modifying therapeutic strategy.
- 8 July 2026
- Published by Wiley in FEBS Open Bio
Open AccessTreatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder for which effective disease‐modifying therapies remain limited. Accumulation of neuronal DNA double‐strand breaks (DSBs) is an early pathological event that contributes to genomic instability and neuronal vulnerability in AD. Therapeutic strategies that enhance DNA repair may therefore be of considerable interest. Here, using the Tg2576 mouse model of AD, we show that treatment with KCL‐286, a selective retinoic acid receptor‐β (RARβ) agonist, reduces neuronal DNA damage. KCL‐286 enhances DSB repair in neurons, in part through upregulation of the DNA repair factor BRCA1, while also attenuating neuroinflammatory activation. In addition, KCL‐286 normalises microglial and astrocytic morphology, consistent with reduced pathological glial activation. Together, these findings demonstrate that selective RARβ activation ameliorates neuronal DNA damage and neuroinflammation in a mouse model of AD, supporting further investigation as a potential disease‐modifying therapeutic strategy.
- Open Access
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1743444
Treatment of spinal cord injury, by restoration of neuronal networks using a combination of surgery and KCL-286, an orally available retinoic acid receptor β drug
The most complicated nerve injuries occur in the spinal nerves. Following traumatic injury at the nerve root attachment to the spinal cord (avulsion), there is degeneration of nerve fibres in the root and spinal cord. The result for the patient is paralysis with sensory loss and typical excruciating severe pain. An obvious fundamental surgical treatment for such injuries is to re-create continuity for the ruptured spinal nerve and the roots detached from the spinal cord. Reimplanting motor spinal roots leads to neuronal growth within the spinal cord and distally in the peripheral nerves, resulting in recovery of shoulder and proximal arm muscles. Sensory function cannot be restored surgically from dorsal root to spinal cord replantation due to the impediment of regrowing sensory fibres at the spinal cord glial scar . However, when a ganglionectomised dorsal root—in effect a peripheral nerve conduit—is implanted into the spinal cord sensory system, intramedullary (secondary) sensory neurons extend distally, resulting in recovery of some sensory function. Patients have profited from this surgery with better functional performance without movement synkinesis and reduced pain. Full functional restoration after a nerve injury cannot be achieved by means of surgery alone due to the impediment of regrowing sensory fibres at the spinal cord glial scar. Embryonic axogenesis was studied to identify pathways required for adult spinal cord injury repair. From this, a key regulator, the retinoic acid receptor β, was identified. This signalling cascade can be reactivated in the injured adult nervous system with the orally available drug KCL-286. This drug has been shown to be safe and tolerated in humans at doses predicted to be used in human spinal cord injuries to provide functional recovery. Therefore, the combination of surgical root implantation and KCL-286 represents a promising therapeutic strategy to improve the quality of life for patients with root avulsions and the broader population of patients with spinal cord injuries.
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1743444
Open AccessTreatment of spinal cord injury, by restoration of neuronal networks using a combination of surgery and KCL-286, an orally available retinoic acid receptor β drug
The most complicated nerve injuries occur in the spinal nerves. Following traumatic injury at the nerve root attachment to the spinal cord (avulsion), there is degeneration of nerve fibres in the root and spinal cord. The result for the patient is paralysis with sensory loss and typical excruciating severe pain. An obvious fundamental surgical treatment for such injuries is to re-create continuity for the ruptured spinal nerve and the roots detached from the spinal cord. Reimplanting motor spinal roots leads to neuronal growth within the spinal cord and distally in the peripheral nerves, resulting in recovery of shoulder and proximal arm muscles. Sensory function cannot be restored surgically from dorsal root to spinal cord replantation due to the impediment of regrowing sensory fibres at the spinal cord glial scar . However, when a ganglionectomised dorsal root—in effect a peripheral nerve conduit—is implanted into the spinal cord sensory system, intramedullary (secondary) sensory neurons extend distally, resulting in recovery of some sensory function. Patients have profited from this surgery with better functional performance without movement synkinesis and reduced pain. Full functional restoration after a nerve injury cannot be achieved by means of surgery alone due to the impediment of regrowing sensory fibres at the spinal cord glial scar. Embryonic axogenesis was studied to identify pathways required for adult spinal cord injury repair. From this, a key regulator, the retinoic acid receptor β, was identified. This signalling cascade can be reactivated in the injured adult nervous system with the orally available drug KCL-286. This drug has been shown to be safe and tolerated in humans at doses predicted to be used in human spinal cord injuries to provide functional recovery. Therefore, the combination of surgical root implantation and KCL-286 represents a promising therapeutic strategy to improve the quality of life for patients with root avulsions and the broader population of patients with spinal cord injuries.
- Open Access
- 4 November 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1491745
Editorial: The role of retinoic acid signaling in maintenance and regeneration of the CNS: from mechanisms to therapeutic targeting
Whilst originally regarded as a nuclear signalling, it is now recognised that RA can exert important functions through non-canonical pathways. Piazza et al, Frontiers | Non-canonical retinoid signaling in neural development, regeneration and synaptic function (frontiersin.org) review these in depth and discuss their importance in activating protein kinase C (PKC), PI3K/AKT3 and ERK1/2 signalling in neural development, nerve regeneration and synapse formation. As these pathways are highly relevant clinically, synthetic retinoids have been developed that induce axonal regeneration by activating genomic (RAR/RXR) and non-genomic (ERK1/2 kinase) pathways (Khatib et al., 2019).Despite the multitude of regenerative pathways governed by RA signalling, all-trans RA itself is not an attractive CNS therapeutic. Not only does it have poor drug-like properties, is associated with liver toxicity, and is rapidly catabolised by CYP26 enzymes, but it is also a pan-RAR agonist. Since these receptors are widely expressed, undesirable effects, both inside and outside of the CNS, are likely to occur at pharmacological doses. In addition, the spatiotemporal fine-tunning of activation of specific RARs in repair mechanisms, such as in spinal cord regeneration for instance, where coordination of RAR and is required, cannot be achieved with RA (Goncalves et al., 2019b). The challenge is to synthesise receptor specific drugs that overcome current toxicities (Borthwick et al., 2020) and or target retinoids to the area of interest, using for example liposomes (Ferreira et al., 2020).To date there are only six retinoids that have entered the clinic, these are pan-RARs (tretinoin, a gel formulation, isotretinoin, oral formulation) (Baldwin et al.;Layton, 2009) and a RAR/ agonist (adapalene, a gel formulation) for treatment of acne (Rusu et al., 2020), one is a RAR/ agonist (tamibarotene), for the treatment of acute promyelocytic leukaemia (Nagai and Ambinder, 2023), and an RXR agonist (bexarotene) for cutaneous T cell lymphoma (Scarisbrick et al., 2013).Recent work has developed a RAR selective agonist, C286, which is less lipophilic than current clinical retinoids, does not have their typical liabilities, has good oral availability and can cross the blood brain barrier (Goncalves et al., 2019a).The paper by Goncalves et al, Frontiers | C286 an orally available retinoic acid receptor agonist drug regulates multiple pathways to achieve spinal cord injury repair (frontiersin.org) further validates the use of C286 to stimulate axonal/neurite outgrowth and highlights the numerous pathways it regulates to achieve that effect. These pathways are involved in synaptogenesis, axonal outgrowth and modulation of the extracellular matrix. and are present in different rodent models of nerve injury, and across species, human derived neurons significantly increased neurite outgrowth in response to C286 treatment. This is important as it suggests that RARb signalling through C286 evokes the same reparative mechanisms in different nerve injuries and in different species, thus being predictive of successful efficacy in humans. The dose used in the proof-of-concept studies (POC) does not exceed the no -observedadverse -effect level (NOAEL) and use of clinical retinoids which are not RARb selective do not give a functional output in nerve injury. Taken together the data suggests that P IIA trials are merited in acute nerve injuries and given the cross over in pathways with chronic CNS injury the drug may be of use here too.With regards to RXR signalling, given the difficulty in developing specific agonists with a good safety profile, a possible approach is to target the orphan nuclear receptor they partner with. For instance, Magan et al, Frontiers | Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System (frontiersin.org) show that the farnesoid X receptor (FXR) is expressed in the hypothalamus and is involved in energy homeostasis. They activate the FXR/RXR with FXR agonist GW4064 so negating the use of an RXR agonist such as bexarotene and therefore a more specific outcome is achieved. The delivery of the agonist is done by intracerebroventricular (ICV) treatment to avoid activating peripheral FXR. Similarly, Zhang et al, Frontiers | Regulation of nuclear factor erythroid-2-related factor 2 as a potential therapeutic target in intracerebral hemorrhage (frontiersin.org) review the role of Nuclear factor erythroid-2-related factor 2 (Nrf2) in preventing oxidative stress in stroke and therefore mitigating brain injury. There are a number of pathways discussed that can increase the expression of NrF2, and one of these is nuclear orphan receptor, Peroxisome proliferator-activated receptor γ (PPARγ). Agonists of PPAR include thiazolidinediones which are used to treat diabetes mellitus although as with current FXR agonists they need to be developed for better brain penetration to treat CNS disease and or a better delivery mechanism.In conclusion, the research topic has brought new pathways involved in CNS repair that are under the regulation of the retinoid signalling. This provides a fertile platform for further target validation and translational research studies to pave the way for novel therapeutic developments for a wide umbrella of neurodegenerative diseases.
- 4 November 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1491745
Open AccessEditorial: The role of retinoic acid signaling in maintenance and regeneration of the CNS: from mechanisms to therapeutic targeting
Whilst originally regarded as a nuclear signalling, it is now recognised that RA can exert important functions through non-canonical pathways. Piazza et al, Frontiers | Non-canonical retinoid signaling in neural development, regeneration and synaptic function (frontiersin.org) review these in depth and discuss their importance in activating protein kinase C (PKC), PI3K/AKT3 and ERK1/2 signalling in neural development, nerve regeneration and synapse formation. As these pathways are highly relevant clinically, synthetic retinoids have been developed that induce axonal regeneration by activating genomic (RAR/RXR) and non-genomic (ERK1/2 kinase) pathways (Khatib et al., 2019).Despite the multitude of regenerative pathways governed by RA signalling, all-trans RA itself is not an attractive CNS therapeutic. Not only does it have poor drug-like properties, is associated with liver toxicity, and is rapidly catabolised by CYP26 enzymes, but it is also a pan-RAR agonist. Since these receptors are widely expressed, undesirable effects, both inside and outside of the CNS, are likely to occur at pharmacological doses. In addition, the spatiotemporal fine-tunning of activation of specific RARs in repair mechanisms, such as in spinal cord regeneration for instance, where coordination of RAR and is required, cannot be achieved with RA (Goncalves et al., 2019b). The challenge is to synthesise receptor specific drugs that overcome current toxicities (Borthwick et al., 2020) and or target retinoids to the area of interest, using for example liposomes (Ferreira et al., 2020).To date there are only six retinoids that have entered the clinic, these are pan-RARs (tretinoin, a gel formulation, isotretinoin, oral formulation) (Baldwin et al.;Layton, 2009) and a RAR/ agonist (adapalene, a gel formulation) for treatment of acne (Rusu et al., 2020), one is a RAR/ agonist (tamibarotene), for the treatment of acute promyelocytic leukaemia (Nagai and Ambinder, 2023), and an RXR agonist (bexarotene) for cutaneous T cell lymphoma (Scarisbrick et al., 2013).Recent work has developed a RAR selective agonist, C286, which is less lipophilic than current clinical retinoids, does not have their typical liabilities, has good oral availability and can cross the blood brain barrier (Goncalves et al., 2019a).The paper by Goncalves et al, Frontiers | C286 an orally available retinoic acid receptor agonist drug regulates multiple pathways to achieve spinal cord injury repair (frontiersin.org) further validates the use of C286 to stimulate axonal/neurite outgrowth and highlights the numerous pathways it regulates to achieve that effect. These pathways are involved in synaptogenesis, axonal outgrowth and modulation of the extracellular matrix. and are present in different rodent models of nerve injury, and across species, human derived neurons significantly increased neurite outgrowth in response to C286 treatment. This is important as it suggests that RARb signalling through C286 evokes the same reparative mechanisms in different nerve injuries and in different species, thus being predictive of successful efficacy in humans. The dose used in the proof-of-concept studies (POC) does not exceed the no -observedadverse -effect level (NOAEL) and use of clinical retinoids which are not RARb selective do not give a functional output in nerve injury. Taken together the data suggests that P IIA trials are merited in acute nerve injuries and given the cross over in pathways with chronic CNS injury the drug may be of use here too.With regards to RXR signalling, given the difficulty in developing specific agonists with a good safety profile, a possible approach is to target the orphan nuclear receptor they partner with. For instance, Magan et al, Frontiers | Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System (frontiersin.org) show that the farnesoid X receptor (FXR) is expressed in the hypothalamus and is involved in energy homeostasis. They activate the FXR/RXR with FXR agonist GW4064 so negating the use of an RXR agonist such as bexarotene and therefore a more specific outcome is achieved. The delivery of the agonist is done by intracerebroventricular (ICV) treatment to avoid activating peripheral FXR. Similarly, Zhang et al, Frontiers | Regulation of nuclear factor erythroid-2-related factor 2 as a potential therapeutic target in intracerebral hemorrhage (frontiersin.org) review the role of Nuclear factor erythroid-2-related factor 2 (Nrf2) in preventing oxidative stress in stroke and therefore mitigating brain injury. There are a number of pathways discussed that can increase the expression of NrF2, and one of these is nuclear orphan receptor, Peroxisome proliferator-activated receptor γ (PPARγ). Agonists of PPAR include thiazolidinediones which are used to treat diabetes mellitus although as with current FXR agonists they need to be developed for better brain penetration to treat CNS disease and or a better delivery mechanism.In conclusion, the research topic has brought new pathways involved in CNS repair that are under the regulation of the retinoid signalling. This provides a fertile platform for further target validation and translational research studies to pave the way for novel therapeutic developments for a wide umbrella of neurodegenerative diseases.
- Open Access
- 20 August 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1411384
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair
Retinoic acid receptor β2 (RARβ2) is an emerging therapeutic target for spinal cord injuries (SCIs) with a unique multimodal regenerative effect. We have developed a first-in-class RARβ agonist drug, C286, that modulates neuron-glial pathways to induce functional recovery in a rodent model of sensory root avulsion. Here, using genome-wide and pathway enrichment analysis of avulsed rats' spinal cords, we show that C286 also influences the extracellular milieu (ECM). Protein expression studies showed that C286 upregulates tenascin-C, integrin-α9, and osteopontin in the injured cord. Similarly, C286 remodulates these ECM molecules, hampers inflammation and prevents tissue loss in a rodent model of spinal cord contusion C286. We further demonstrate C286's efficacy in human iPSC-derived neurons, with treatment resulting in a significant increase in neurite outgrowth. Additionally, we identify a putative efficacy biomarker, S100B, which plasma levels correlated with axonal regeneration in nerve-injured rats. We also found that other clinically available retinoids, that are not RARβ specific agonists, did not lead to functional recovery in avulsed rats, demonstrating the requirement for RARβ specific pathways in regeneration. In a Phase 1 trial, the single ascending dose (SAD) cohorts showed increases in expression of RARβ2 in white blood cells correlative to increased doses and at the highest dose administered, the pharmacokinetics were similar to the rat proof of concept (POC) studies. Collectively, our data suggests that C286 signalling in neurite/axonal outgrowth is conserved between species and across nerve injuries. This warrants further clinical testing of C286 to ascertain POC in a broad spectrum of neurodegenerative conditions.
- 20 August 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1411384
Open AccessC286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair
Retinoic acid receptor β2 (RARβ2) is an emerging therapeutic target for spinal cord injuries (SCIs) with a unique multimodal regenerative effect. We have developed a first-in-class RARβ agonist drug, C286, that modulates neuron-glial pathways to induce functional recovery in a rodent model of sensory root avulsion. Here, using genome-wide and pathway enrichment analysis of avulsed rats' spinal cords, we show that C286 also influences the extracellular milieu (ECM). Protein expression studies showed that C286 upregulates tenascin-C, integrin-α9, and osteopontin in the injured cord. Similarly, C286 remodulates these ECM molecules, hampers inflammation and prevents tissue loss in a rodent model of spinal cord contusion C286. We further demonstrate C286's efficacy in human iPSC-derived neurons, with treatment resulting in a significant increase in neurite outgrowth. Additionally, we identify a putative efficacy biomarker, S100B, which plasma levels correlated with axonal regeneration in nerve-injured rats. We also found that other clinically available retinoids, that are not RARβ specific agonists, did not lead to functional recovery in avulsed rats, demonstrating the requirement for RARβ specific pathways in regeneration. In a Phase 1 trial, the single ascending dose (SAD) cohorts showed increases in expression of RARβ2 in white blood cells correlative to increased doses and at the highest dose administered, the pharmacokinetics were similar to the rat proof of concept (POC) studies. Collectively, our data suggests that C286 signalling in neurite/axonal outgrowth is conserved between species and across nerve injuries. This warrants further clinical testing of C286 to ascertain POC in a broad spectrum of neurodegenerative conditions.
- Open Access
- 9 August 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (12) , 3573-3583
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants
Aims: KCL‐286 is an orally available agonist that activates the retinoic acid receptor (RAR) β2, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). This adaptive dose escalation study evaluated the tolerability, safety and pharmacokinetics and pharmacodynamic activity of KCL‐286 in male healthy volunteers to establish dosing to be used in the SCI patient population.Methods: The design was a double blind, randomized, placebo‐controlled dose escalation study in 2 parts: a single ascending dose adaptive design with a food interaction arm, and a multiple ascending dose design. RARβ2 mRNA expression was evaluated in white blood cells.Results: At the highest single and multiple ascending doses (100 mg), no trends or clinically important differences were noted in the incidence or intensity of adverse events (AEs), serious AEs or other safety assessments with none leading to withdrawal from the study. The AEs were dry skin, rash, skin exfoliation, raised liver enzymes and eye disorders. There was an increase in mean maximum observed concentration and area under the plasma concentration–time curve up to 24 h showing a trend to subproportionality with dose. RARβ2 was upregulated by the investigational medicinal product in white blood cells.Conclusion: KCL‐286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models. Target engagement shows the drug candidate activates its receptor. These findings support further development of KCL‐286 as a novel oral treatment for SCI.
- 9 August 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (12) , 3573-3583
Open AccessPhase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants
Aims: KCL‐286 is an orally available agonist that activates the retinoic acid receptor (RAR) β2, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). This adaptive dose escalation study evaluated the tolerability, safety and pharmacokinetics and pharmacodynamic activity of KCL‐286 in male healthy volunteers to establish dosing to be used in the SCI patient population.Methods: The design was a double blind, randomized, placebo‐controlled dose escalation study in 2 parts: a single ascending dose adaptive design with a food interaction arm, and a multiple ascending dose design. RARβ2 mRNA expression was evaluated in white blood cells.Results: At the highest single and multiple ascending doses (100 mg), no trends or clinically important differences were noted in the incidence or intensity of adverse events (AEs), serious AEs or other safety assessments with none leading to withdrawal from the study. The AEs were dry skin, rash, skin exfoliation, raised liver enzymes and eye disorders. There was an increase in mean maximum observed concentration and area under the plasma concentration–time curve up to 24 h showing a trend to subproportionality with dose. RARβ2 was upregulated by the investigational medicinal product in white blood cells.Conclusion: KCL‐286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models. Target engagement shows the drug candidate activates its receptor. These findings support further development of KCL‐286 as a novel oral treatment for SCI.
- Open Access
- 1 October 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (20) , 115664
Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review
- 1 October 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (20) , 115664
Open AccessRecent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review
- Open Access
- 1 August 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (16) , 2440-2441
Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000]
- 1 August 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (16) , 2440-2441
Open AccessCorrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000]
- Open Access
- 1 April 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (8) , 995-1000
Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury
- 1 April 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (8) , 995-1000
Open AccessDiscovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury